December 3, 2024 11:12 AM EST
Deals

Re­lay li­cens­es can­cer drug to Ko­re­an biotech for $75M

Elizabeth Cairns

Senior biopharma journalist

Re­lay Ther­a­peu­tics said last year it would de­lay the reg­u­la­to­ry fil­ing of li­rafu­gra­tinib in bile duct can­cer. Now it’s step­ping away from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

Lil­ly to ac­quire can­cer biotech Scor­pi­on, which shares a co-founder with Loxo

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

A mixed year for deals and dol­lars left biotech ex­ecs hun­gry for a bet­ter 2025

Sage sues Bio­gen days af­ter $469M buy­out of­fer

A service from the Financial Times